Deeb Asma, Al Yaarubi Saif, Abbas Bassam Bin, Al Jubeh Jamal, Chaturvedi Deepti, Al Hassani Noura, Mutair Angham, Al Masri Neamat, Al Sanad Yazan, Al Shidhani Azza, Mahmoud Noha Samir, Alherbish Abdullah, Savage Martin O
Sheikh Shahbout Medical City & Khalifa University, Abu Dhabi, United Arab Emirates.
College of Medicine, Sultan Qaboos University Hospital, Muscat, Oman.
Front Pediatr. 2022 Feb 28;10:839278. doi: 10.3389/fped.2022.839278. eCollection 2022.
This study aimed to assess patient perceptions of the use of the EasyPod™ growth hormone delivery device and its association with compliance.
This cross-sectional, multicenter study was conducted in six centers from three countries (United Arab Emirates, Oman, and Saudi Arabia,) between March 2020 and June 2020. Children and adolescents aged 3-18 years, diagnosed with growth disorders and receiving rhGH through the EasyPod™ device were enrolled. Patients and caregivers were given a pre-set questionnaire that evaluated patient satisfaction, preference for technical and personalized features, and device drawbacks. The results were analyzed using independent measures of analysis of variance to evaluate the association of higher satisfaction with device features and better compliance.
A total of 186 patients were enrolled in the study. Of these, 45.7% had GH deficiency. The mean age (±SD) of patients was 11.8 (±2.76) years; 117 (62.90%) were males. Average compliance was 87%. One hundred patients (53.76%) had injection compliance of ≥90%. Amongst these patients, 74%, 68%, and 77% top-scored (5/5) the technical features of hidden needle, skin sensor, and pre-set dosing, respectively, compared to top scores by 39%, 34%, and 51% patients in the <90% compliance group (-value <0.05). Similarly, a statistically significant difference was observed between the groups (-value <0.05) in the perception of the usefulness of the tracking features such as display of history of injected doses (78% vs. 47.7%), a reminder for medicine remaining (46% vs. 23.3%) and battery power indicator (48% vs. 20.9%). Personal screen messages were associated with higher compliance while the requirement to keep the device in the fridge was reported as the most inconvenient feature by 56% of patients in the higher compliance group as against 39.5% in the lower compliance group (-value <0.05). There was no statistically significant difference in the intensity of pain reported in the two compliance groups.
Our study showed that there is a statistically significant association between better perception of device features and higher compliance.
本研究旨在评估患者对EasyPod™生长激素给药装置使用的看法及其与依从性的关联。
本横断面、多中心研究于2020年3月至2020年6月在来自三个国家（阿拉伯联合酋长国、阿曼和沙特阿拉伯）的六个中心进行。纳入3至18岁被诊断为生长障碍并通过EasyPod™装置接受重组人生长激素（rhGH）治疗的儿童和青少年。患者和护理人员被给予一份预先设定的问卷，该问卷评估患者满意度、对技术和个性化特征的偏好以及装置缺点。使用独立方差分析方法分析结果，以评估更高的满意度与装置特征及更好的依从性之间的关联。
共有186名患者纳入本研究。其中，45.7%患有生长激素缺乏症。患者的平均年龄（±标准差）为11.8（±2.76）岁；117名（62.90%）为男性。平均依从性为87%。100名患者（53.76%）的注射依从性≥90%。在这些患者中，分别有74%、68%和77%在隐藏针头、皮肤传感器和预设剂量的技术特征方面获得最高分（5/5），而依从性<90%组的患者中这一比例分别为39%、34%和51%（P值<0.05）。同样，两组之间在对诸如注射剂量历史显示（78%对47.7%）、剩余药物提醒（46%对23.3%）和电池电量指示器（48%对20.9%）等追踪功能有用性的认知方面存在统计学显著差异（P值<0.05）。个性化屏幕信息与更高的依从性相关，而在依从性较高组中，56%的患者认为将装置保存在冰箱中的要求是最不方便的特征，而依从性较低组中这一比例为39.5%（P值<0.05）。两个依从性组报告的疼痛强度没有统计学显著差异。
我们的研究表明，对装置特征更好的认知与更高的依从性之间存在统计学显著关联。
